David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...
The FDA approves zilganersen, the first disease-modifying Alexander disease therapy, offering rare disease developers a trial ...
Pharma Insights - Thought Leadership from Marketers | Sponsored Content | Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...
Novartis's up-to-$3.2 billion licensing deal for Alteogen's ALT-B4 hyaluronidase enzyme is the fourth subcutaneous-conversion ...
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about what’s new for CPHI Milan this year, ...
Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...
As increasingly complex, poorly water-soluble molecules enter development, AustinPx helps developers look beyond near-term ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol ...
Robert Holt, PhD, associate director, Pharmaceutical Science, digiM Solution, discusses microstructure intelligence in more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results